Latest AI and machine learning research in alzheimer's disease for healthcare professionals.
Prior research suggests that meditation may slow brain aging and reduce the risk of Alzheimer’s dise...
Neuron loss is a key feature of neurodegenerative diseases often leading to brain atrophy detectable...
Alzheimer’s Disease and Related Dementias (ADRD) affect millions worldwide and can begin over a deca...
Cognitive decline affects approximately 40% of Parkinson’s disease (PD) patients within 10 years of ...
Alzheimer’s disease (AD) involves early molecular changes beyond amyloid-β (Aβ) and tau, that create...
Retinal fundus images offer a non-invasive window into systemic aging. Here, we fine-tuned a foundat...
Early and accurate prediction of Alzheimer’s disease (AD) from accessible clinical data remains a si...
APOE-ε4, the strongest genetic risk factor for Alzheimer’s disease (AD), is linked to early motor vu...
Alzheimer’s Disease (AD) is a progressive neurodegenerative disorder that primarily affects cognitiv...
Predicting the likelihood of developing Alzheimer’s disease (AD) dementia in at-risk individuals is ...
Clinicians currently lack reliable tools to determine, at the point of mild cognitive impairment (MC...
Alzheimer’s disease (AD) has greater prevalence in women and lacks effective treatments. Integrating...
Dementia in Lewy body diseases (LBD) is common and arises through heterogeneous and incompletely und...
Convolutional neural networks (CNNs) have been the standard for computer vision tasks including appl...
Quantitative PET underpins diagnosis and treatment monitoring in neurodegenerative disease, yet syst...
Patients with rare diseases often struggle to find accurate medical information, and large language ...
Accurate clinical and pathological diagnoses are essential in neurodegenerative diseases, especially...
Alzheimer’s disease is a progressive neurodegenerative disorder where early detection remains diffic...
The heterogeneity of brain aging is a hallmark of neurological and psychiatric disorders, yet machin...
Second-generation antipsychotics (SGAs) are frequently used off-label to manage behavioral symptoms ...
Dementia encompasses diverse clinical syndromes where diseases of the brain can manifest as impaired...